文献速递淋巴瘤

SWOG S0816 五年随访:PET 适应治疗晚期霍奇金淋巴瘤的局限与价值

Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma.
PubMed 文献 · Blood · 2019-01-01

SWOG S0816 研究对 331 例晚期霍奇金淋巴瘤患者行 PET 适应治疗,中位随访 5.9 年。PET2 阴性率 82%,阳性率 18%;5 年 PFS 全组 74%,PET2- 组 76%,PET2+ 组 66%;5 年 OS 全组 94%。

要点

  • PET2 阴性率 82%,阳性率 18%;5 年 PFS 全组 74%,PET2- 组 76% vs PET2+ 组 66%。
  • 5 年 OS 全组 94%;PET2- 患者近 25% 出现复发事件,提示 ABVD 及 PET2 阴性预测价值有限。

核心结论

  • 晚期霍奇金淋巴瘤患者经 S0816 方案治疗后长期 OS 仍高,但 PET2 阴性患者近 25% 出现复发事件,提示 ABVD 治疗和 PET2 阴性预测价值存在局限。
  • PET2 阳性患者接受 eBEACOPP 后 PFS 良好,但与历史对照相比第二恶性肿瘤发生率高。

研究设计与样本

  • SWOG S0816 为 PET 适应治疗研究,患者接受 2 周期 ABVD 后行 PET2 评估;达 CR 者继续 4 周期 ABVD,未达 CR 者换用 6 周期 eBEACOPP。
  • 中位随访 5.9 年后,分析 331 例经中心 PET2 复核的合格患者。

主要发现

  • PET2 阴性 82%,阳性 18%。
  • 全组估计 5 年 PFS 74%(95%CI 69%-79%),5 年 OS 94%(95%CI 91%-96%)。
  • PET2- 组 5 年 PFS 76%(95%CI 70%-81%)vs PET2+ 组 66%(95%CI 52%-76%)。
  • PET2- 患者中近 25% 出现复发事件。

关键数值与推荐

  • PET2 阴性:82%;PET2 阳性:18%。
  • 全组 5 年 PFS 74%(95%CI 69%-79%),5 年 OS 94%(95%CI 91%-96%)。
  • PET2- 组 5 年 PFS 76%(95%CI 70%-81%),PET2+ 组 5 年 PFS 66%(95%CI 52%-76%)。

临床怎么用

  • 晚期霍奇金淋巴瘤采用 PET 适应治疗时,需重视长期随访。
  • PET2 阴性患者仍有近 25% 复发事件,PET2 阴性预测价值有限。
  • PET2 阳性患者接受 eBEACOPP 后 PFS 良好,但第二恶性肿瘤发生率较高。
  • 结果强调需要更有效且毒性更低的晚期霍奇金淋巴瘤治疗方法。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with advanced-stage Hodgkin lymphoma (HL) demonstrated excellent 2-year progression-free survival (PFS) after receiving positron emission tomography (PET)-adapted therapy on SWOG S0816. Patients received 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Patients achieving complete response (CR) on PET scan following cycle 2 of ABVD (PET2) continued 4 additional cycles of ABVD. Patients not achieving CR on PET2 were switched to escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP) for 6 cycles. After a median follow-up of 5.9 years, a subset of 331 eligible patients with central review of PET2 was analyzed. PET2 was negative in 82% and positive in 18%. For all patients, the estimated 5-year PFS and OS was 74% (95% confidence interval [CI], 69%-79%) and 94% (95% CI, 91%-96%), respectively. For PET2- and PET2+ patients, the 5-year PFS was 76% (95% CI, 70%-81%) and 66% (95% CI, 52%-76%), respectively. Seven (14%) and 6 (2%) patients reported second cancers after treatment with eBEACOPP and ABVD, respectively (P = .001). Long-term OS of HL patients treated on S0816 remains high. Nearly 25% of PET2- patients experienced relapse events, demonstrating limitations ABVD therapy and of the negative predictive value of PET2. In PET2+ patients who received eBEACOPP, PFS was favorable, but was associated with a high rate of second malignancies compared with historical controls. Our results emphasize the importance of long-term follow-up, and the need for more efficacious and less toxic therapeutic approaches for advanced-stage HL patients. This trial was registered at www.clinicaltrials.gov as #NCT00822120.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Stephens DM, Li H, Schöder H, et al. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood. 2019. PMID: 31331918. doi:10.1182/blood.2019000719

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。